Aprea Therapeutics, Inc. announced updated interim results from its ongoing Phase 1 ACESOT-1051 trial of APR-1051, an investigational oral WEE1 inhibitor. The data were presented on November 20, 2026, at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
As of the November 1, 2026 data cutoff, 56 patients had received APR-1051 across all dose levels. Among 43 evaluable patients, two patients with PPP2R1A-mutated uterine cancers achieved RECIST 1.1 partial responses: one confirmed and ongoing for more than 10 months, and one unconfirmed. Sixteen patients experienced stable disease, with five of those lasting four months or longer.
Pharmacodynamic data indicated WEE1 target engagement, with reductions of at least 50% in phosphorylated CDK1-Y15 observed in 84% of 25 evaluable patients. The safety profile included one dose-limiting toxicity (DLT) and Grade 3/4 neutropenia in 7% of patients. The most common all-grade treatment-related adverse events were nausea (41%), fatigue (25%), and diarrhea (14%).
Pharmacokinetic analysis supported once-daily administration, with an approximately 18-hour median half-life. Aprea plans to enroll at least 50 patients with uterine serous carcinoma or cyclin E-overexpressing platinum-resistant ovarian cancer, with completion of dose escalation and expansion enrollment expected in the second quarter of 2027.